Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
2011

Efficacy of Fumaric Acid Esters in Mouse Models of Huntington's Disease

Sample size: 47 publication 10 minutes Evidence: high

Author Information

Author(s): Ellrichmann Gisa, Petrasch-Parwez Elisabeth, Lee De-Hyung, Reick Christiane, Arning Larissa, Saft Carsten, Gold Ralf, Linker Ralf A.

Primary Institution: Ruhr-University Bochum, Germany

Hypothesis

Does dimethylfumarate (DMF) have therapeutic efficacy in mouse models of Huntington's disease?

Conclusion

DMF treatment leads to preserved body weight, prolonged survival, and improved motor functions in mouse models of Huntington's disease.

Supporting Evidence

  • DMF treatment significantly prevented weight loss in R6/2 mice.
  • Average survival in the DMF group was 100.5 days compared to 94.0 days in the placebo group.
  • DMF treatment resulted in a significant preservation of morphologically intact neurons in the striatum and motor cortex.

Takeaway

Researchers tested a drug called DMF on mice with Huntington's disease and found it helped them live longer and move better.

Methodology

The study used R6/2 and YAC128 transgenic mice, treated them with DMF, and assessed their weight, survival, and motor functions through various tests.

Limitations

The study design does not allow conclusions on overall loss of striatal or motor cortex neuron numbers.

Participant Demographics

Male R6/2 and YAC128 mice were used in the study.

Statistical Information

P-Value

p=0.05

Confidence Interval

DMF 97.7–104.6 vs. methocel 91.22–99.6 days

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016172

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication